Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Selected as Preferred Partner for UK's 100,000 Genomes Project

NEW YORK (GenomeWeb) – Illumina said in a regulatory filing this week that Genomics England has selected Illumina Cambridge as a preferred partner for the 100,000 Genomes Project.

The project was created by the UK government in late 2012 to sequence the genomes of up to 100,000 people in an effort to gain a better insight into cancer and other diseases and to better treat them. Genomics England, a company owned by the UK Department of Health, was set up to run the 100,000 Genomes Project.

Illumina Cambridge, a subsidiary of the San Diego-based company, was selected by Genomics England as a preferred partner for the sequencing part of the project, Illumina said in a document filed with the US Securities and Exchange Commission, adding that a definitive agreement is being worked out.

Last fall, Genomics England, Illumina, and the University of Cambridge said that they would sequence 10,000 whole genomes of children and adults with rare genetic diseases as part of a pilot project under the 100,000 Genomes Project.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.